Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
10.08
+0.65 (6.89%)
At close: Oct 8, 2025, 4:00 PM EDT
10.15
+0.07 (0.69%)
After-hours: Oct 8, 2025, 7:58 PM EDT
Kura Oncology Revenue
Kura Oncology had revenue of $15.29M in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $83.28M. In the year 2024, Kura Oncology had annual revenue of $53.88M.
Revenue (ttm)
$83.28M
Revenue Growth
n/a
P/S Ratio
10.56
Revenue / Employee
$433,745
Employees
192
Market Cap
874.92M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 53.88M | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
KURA News
- 5 days ago - Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 days ago - Kura Oncology, Inc. (KURA) Presents at UBS Virtual Oncology Day Transcript - Seeking Alpha
- 7 days ago - Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) - GlobeNewsWire
- 9 days ago - Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML) - GlobeNewsWire
- 13 days ago - Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology - GlobeNewsWire
- 14 days ago - Kura Oncology to Participate in Upcoming Investor Conference - GlobeNewsWire
- 19 days ago - Kura Oncology Transitioning To Commercial Stage: Why I Choose To Buy - Seeking Alpha
- 22 days ago - Kura Oncology, Inc. - Special Call - Seeking Alpha